CAJ | 학술논문

目的探讨白介素(IL)-22及其相关因子IL-23p19、IL-6在寻常性银屑病患者外周血单一核细胞(PBMC)及血清中表达的意义.方法采用实时定量RT-PCR法检测寻常性银屑病患者及正常人对照者外周血PBMC中IL-22 mRNA、IL-23p19 mRNA及IL-6 mRNA的水平;采用ELISA法检测寻常性银屑病患者及正常人对照者血清和PBMC培养上清中IL-22的分泌水平.结果银屑病组和正常人对照组PBMC中IL-22 mRNA的相对表达量分别为4.48 4±2.64和2.35±0.91;IL-23p19 mRNA的相对表达量分别为6.07±4.09和2.61 4±1.46;IL-6 mRNA的相对表达量分别为3.87 4±1.49和1.48 4±0.62;差异均有统计学意义(P<0.01).ELISA检测发现,银屑病组和正常人对照组血清中IL-22的水平分别为(86.23 ±25.58)ng/L和(43.67±14.82)ng/L(P<0.01),PBMC培养上清中IL-22的水平分别为(119.11±21.51)ng/L和(57.70±13.17)ng/L(P<0.01).结论寻常性银屑病患者PBMC和血清中过度表达IL-22,提示IL-22可能参与银屑病的发病机制.
목적 탐토백개소(IL)-22급기상관인자IL-23p19、IL-6재심상성은설병환자외주혈단일핵세포(PBMC)급혈청중표체적의의.방법 채용실시정량RT-PCR법검측심상성은설병환자급정상인대조자외주혈PBMC중IL-22 mRNA、IL-23p19 mRNA급IL-6 mRNA적수평;채용ELISA법검측심상성은설병환자급정상인대조자혈청화PBMC배양상청중IL-22적분비수평.결과 은설병조화정상인대조조PBMC중IL-22 mRNA적상대표체량분별위4.48 4±2.64화2.35±0.91;IL-23p19 mRNA적상대표체량분별위6.07±4.09화2.61 4±1.46;IL-6 mRNA적상대표체량분별위3.87 4±1.49화1.48 4±0.62;차이균유통계학의의(P<0.01).ELISA검측발현,은설병조화정상인대조조혈청중IL-22적수평분별위(86.23 ±25.58)ng/L화(43.67±14.82)ng/L(P<0.01),PBMC배양상청중IL-22적수평분별위(119.11±21.51)ng/L화(57.70±13.17)ng/L(P<0.01).결론 심상성은설병환자PBMC화혈청중과도표체IL-22,제시IL-22가능삼여은설병적발병궤제.
Objective To investigate the expressions and significance of IL-22 and related cytokines (IL-23pl9 and IL-6) in sera and PBMCs of patients with psoriasis. Methods Sera and PBMCs were obtained from the venous blood samples from 58 patients with psoriasis vulgaris and 20 normal human controls. The PBMCs were subjected to culture for 5 hours followed by the collection of cells and culture supernatant. Then,quantitative real-time RT-PCR was used to examine the mRNA expressions of IL-22, IL-23pl9 and IL-6 in PBMCs, enzyme-linked immunosorbent assay (ELJSA) to detect the level of IL-22 protein in the sera and culture supernatant of PBMCs. Results In the patients with psoriasis and controls, the relative expression level in PBMCs was 4.48 ± 2.64 and 2.35 ± 0.91 respectively for IL-22 mRNA, 6.07 ± 4.09 and 2.61 ± 1.46 respectively for IL-23pl9 mRNA, 3.87 ± 1.49 and 1.48 ± 0.62 respectively for IL-6 mRNA; significant differences were observed between the two groups in all the above parameters (all P < 0.01). ELISA revealed that the level of IL-22 protein in the patients and controls was (86.23 ± 25.58) ng/L and (43.67 ± 14.82) ng/L respectively in the sera (P< 0.01), (119.11 ± 21.51) ng/L and (57.70 ± 13.17) ng/L respectively in the culture supernatant of PBMCs (P< 0.01). Conclusion There is an overexpression of IL-22 in the PBMCs and sera of patients with psoriasis, implying that IL-22 is involved in the pathogenesis of psoriasis.